# OnCo record nct06051695 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06051695/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06051695", "NCT06051695" ;
  schema:name "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression"@en ;
  schema:alternateName "EVEREST-2"@en ;
  schema:description "A phase 1/2 trial of A2B694 in colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, ovarian cancer and mesothelioma, run by A2 Biotherapeutics Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06051695/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06051695> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-04-03" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/mesothelioma/> ;
  onco:companies <https://onco.cc/companies/tempus/>, <https://onco.cc/companies/a2-biotherapeutics/> .